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Anti-angiogenetic cancer therapy is a potential new form for treatment of solid tumours. The av-integrins (avb3, avb5) mediate
the contact of activated endothelial cells to proteins of the extracellular matrix during tumour angiogenesis as a prerequisite
for survival of endothelial cells. The aim of this study was to investigate the effects of application of a methylated cyclic RGD-
peptide as an av-integrin antagonist on angiogenesis, microcirculation, growth and metastasis formation of a solid tumour in
vivo. Experiments were performed in the dorsal skinfold preparation of Syrian Golden hamsters bearing the amelanotic
hamster melanoma A-Mel-3. Animals were injected intraperitoneally with a methylated cyclic RGD-peptide every 12 h, the
control group received an inactive peptide. Microcirculatory parameters of tumour angiogenesis including functional vessel
density, red blood cell velocity, vessel diameter and leucocyte–endothelium interaction were analysed using intravital
microscopy. In an additional study the effects on growth and metastasis of subcutaneous A-Mel-3 were quantiﬁed. Functional
vessel density was markedly reduced on day 3 in treated animals compared to controls (37.2+12.1 vs 105.2+11.2 cm
71;
mean+s.e.m.; P50.05) and increased subsequently in both groups. Red blood cell velocity at day 3 was below values of
controls (0.026+0.01 vs 0.12+0.03 mm s
71; P50.05). No differences were observed in vessel diameters and leucocyte–
endothelium interaction was almost absent in both groups. Furthermore, growth and metastasis of subcutaneous tumours
after administration of the cyclic RGD-peptide was signiﬁcantly delayed in comparison to controls (P50.05). Inhibition of av-
integrins by a cyclic RGD-peptide resulted in signiﬁcant reduction of functional vessel density, retardation of tumour growth
and metastasis in vivo. Taken together, these results implicate RGD-peptides as agents which have anti-tumour and anti-
metastatic activity in vivo.
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Angiogenesis, the growth of new blood vessels from pre-existing
vessels, is involved in several physiological and pathological situa-
tions like wound healing (Clark et al, 1982) and inﬂammatory
diseases (Auerbach and Auerbach, 1994; Folkman, 1995). For
growth and metastasis of solid tumours angiogenesis is the key
prerequisite (Folkman, 1990, 1995). Furthermore, the extent of
vascularisation in solid tumours is an independent prognostic
factor for survival and therapeutic outcome (Weidner et al, 1991,
1993; Graham et al, 1994). Recently, the concept of anti-angioge-
netic therapy for tumours has been proven in animals (O’Reilly
et al, 1997), and this new therapeutic strategy will most likely gain
clinical importance. However, development of anti-angiogenetic
drugs based on the understanding of the mechanisms of angiogen-
esis is still in the early stages.
There is emerging evidence that tumour angiogenesis is regu-
lated by the balance of pro-angiogenic and anti-angiogenic
factors (Liotta et al, 1991; Hanahan and Folkman, 1996). To
establish a vascular system in the tumour it requires the coopera-
tion of a variety of molecules that regulate cellular processes such
as activation of endothelial cells, proliferation, modulation of the
extracellular matrix (ECM), invasion, migration and vascular
remodelling. Members of the integrin class of cell adhesion recep-
tors play a key role in cell–cell and cell–ECM interaction during
the growth of new blood vessels (Hynes, 1992; Luscinskas and
Lawler, 1994). Especially the av-integrins, combined with distinct
b subunits, exhibit a high expression in angiogenesis (Cheresh,
1992; Eliceiri and Cheresh, 1999). av-integrins on endothelial cells
are capable of recognising a variety of ECM proteins with an
exposed Arg-Gly-Asp (RGD) sequence, including vitronectin,
ﬁbronectin, ﬁbrinogen, thrombospondin, proteolysed collagen,
von Willebrand factor and osteopontin (Brooks, 1996). Conse-
quently, antibodies or synthetic RGD-containing peptides
directed against the av-integrins inhibited in vitro endothelial tube
formation or microvessel outgrowth in previous experiments
(Nicosia and Bonanno, 1991; Brooks, 1996; Bayless et al, 2000).
Most recently it was shown that the expression of avb3 and
avb5 by the microvascular endothelium of neuroblastoma is asso-
ciated with the aggressiveness of these tumours (Erdreich-Epstein
et al, 2000).
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especially elucidated by Cheresh and colleagues in a series of
experiments (Brooks et al, 1994a,b). An anti-avb-mAb limited
blood vessel growth of human melanomas, implanted in the chor-
ioallantoic membrane (Brooks et al, 1994b). Application of cyclic
RGD peptide antagonists for avb3 and avb5 disrupted angiogenesis
on the CAM and lead to regression of transplanted tumours
(Brooks et al, 1994a). Interestingly, the antagonists did not affect
pre-existing vessels. The mechanism of action of av-antagonists in
blocking angiogenesis seems to be related to their ability to selec-
tively promote apoptosis of endothelial cells in newly sprouting
blood vessels (Brooks et al, 1994b; Stromblad et al, 1996; Eliceiri
and Cheresh, 1999) and by affecting the function of proteolytic
enzymes such as metalloproteinases (Brooks et al, 1996; 1998).
Recently, a methylated cyclic RGD peptide has been synthesised
as highly active and selective ligand for the av-integrin receptor
(Dechantsreiter et al, 1999). The effects of anti-angiogenic treat-
ment using this cyclic RGD-peptide on growth and angiogenesis
of solid tumours in vivo have not been studied so far. The dorsal
skinfold chamber preparation, bearing a solid homologous trans-
planted tumour, represents a unique and well established tool to
study tumour angiogenesis non-invasively and continuously over
a prolonged period of time in vivo (Asaishi et al, 1981; Endrich
et al, 1982). Direct observation of tumour microvessels in the
dorsal skinfold chamber preparation may provide further insights
into the alterations of angiogenesis during the application of a
potential angiogenesis inhibitor. It was therefore the aim of the
present study to investigate the effects of the cyclic RGD peptide
on tumour angiogenesis, microcirculation, growth and metastasis
of solid tumours in vivo.
MATERIALS AND METHODS
Experiments were performed with male Syrian Golden Hamsters
(6–8 weeks old, 50–60 g body weight (bw)) in accordance with
institutional guidelines after approval of the animal committee of
the Bavarian state. The animals were housed one per cage and
had free access to tap water and standard laboratory food through-
out the experiments. Animals were inspected at least two times a
day by specialised animal colony staff to assure a normal clinical
condition (including appearance, posture, behaviour and physiolo-
gical responses). Particular attention was given to body weight and
any signs of discomfort, ulceration or inﬂammation. All surgical
procedures were performed under pentobarbital anaesthesia
(50 mg kg
71 b.w., i.p.; Nembutal, Sanoﬁa-Leva, Hannover,
Germany). The experiments met all the standards required by the
UKCCCR guidelines for the welfare of animals in experimental
neoplasia (United Kingdom Co-ordinating Committee on Cancer
Research (UKCCCR), 1998).
Dorsal skinfold chamber preparation
For quantiﬁcation of tumour angiogenesis, a dorsal skinfold
chamber preparation consisting of two symmetrical titanium
frames was surgically implanted into the dorsal skin as described
earlier in detail (Asaishi et al, 1981; Endrich et al, 1982). This is
considered to cause the least distress upon the animal because the
dorsal skin is extremely expansible. Following implantation of the
transparent chamber and a recovery period of 48 h from anaes-
thesia and microsurgery, preparations fulﬁlling the criteria of an
intact microcirculation were implanted with 2610
5 cells of the
amelanotic melanoma of the hamster A-Mel-3 (Fortner et al,
1961). Fine polyethylene catheters (PE10, inner diameter
0.28 mm) were permanently inserted into the right jugular vein
48 h before ﬁrst measurement to allow injection of ﬂuorescent
agents for intravital ﬂuorescence microscopy. The animals toler-
ated the dorsal skinfold chamber well and showed no signs of
discomfort.
Assessment of tumour angiogenesis and growth by
intravital microscopy
Quantiﬁcation of tumour angiogenesis using intravital ﬂuorescence
microscopy have been described in detail elsewhere (Asaishi et al,
1981; Dellian et al, 1995, 1996). In brief, the awake animal was
trained to crawl into a transparent plastic tube and was placed
on a custom-made stage under a modiﬁed Leitz microscope
(Orthoplan; Leitz, Munich, Germany). FITC-labelled dextran
(Sigma, Deisenhofen, Germany; MW 500000; 0.05–0.1 ml of a
5% solution in 0.9% NaCl) as a plasma marker and rhodamine
6G (Molecular Probes, Eugene, OR, USA; 0.04 ml of a 0.05% solu-
tion in 0.9% NaCl) to label white blood cells in vivo, were injected
i.v. to visualise microcirculation and leucocyte–endothelium inter-
action, respectively. The used dosage of the applied ﬂuorescence
dye does not have any toxic effect upon the animal. Selective obser-
vation of FITC-labelled plasma was possible using epi-illumination
with a 100 W mercury lamp attached to a Ploemopack illuminator
with a Leitz I2/3 ﬁlter block (excitation 450–490 nm, emission
4515 nm) and rhodamine 6G-stained leucocytes were visualised
using a Leitz N2 ﬁlter block (excitation 530–560 nm, emission
4580 nm). Intravital microscopy was performed 3, 5, 9 and 13
days after implantation of the tumour cells. At least 3–5 sites of
interest per animal were randomly selected in centre and periphery
of the tumour. Images were acquired by a SIT video camera
(C2400-08; Hamamatsu Herrsching, Germany) and recorded on
S-VHS video tape (Sony) for subsequent analysis. Parallel to micro-
vascular observations the area covered by tumour in the chamber
preparation was registered on videotape using a Leitz macroscope
with video camera (XC-77; Sony) to evaluate tumour growth.
The tumour area (mm
2) was quantiﬁed from videotape by digital
image analysis.
Analysis of microcirculatory parameters was performed off-line
from video tape by an image analysis system (Cap Image; Zeintl,
Heidelberg, Germany). This system described in detail by Zeintl
et al (1989) and Klyscz et al (1997) allows measurement of func-
tional vessel density (FVD) as a parameter of angiogenic activity
(Dellian et al, 1996). FVD is deﬁned as the total length of perfused
microvessels per unit area of observation and is given in cm
71.
Red blood cell velocity (vRBC) was quantiﬁed with the line shift
diagram method according to Klyscz et al (1997) in mm s
71. Roll-
ing leucocytes were deﬁned as population of cells temporarily
interacting with the vessel wall and thus having a velocity at least
50% below vRBC in the same vessel. Adherent leucocytes were
given as the number of leucocytes remaining stationary for at least
30 s per square millimetre of vessel wall surface (Atherton and
Born, 1972; Dellian et al, 1996).
Evaluation of tumour growth and metastasis
Male Syrian Golden Hamsters (weight, age and housing as
described above) were anaesthetised with pentobarbital and the
dorsal skin was shaven and chemically depilated (Pilcamed,
Schwarzkopf, Germany). Cells (4 to 6610
6) of the A-Mel-3 were
suspended in a 10 ml volume and injected s.c. over the lumbosacral
region of the dorsal skin. This is considered to cause the least
distress upon the animal because the dorsal skin is extremely
expansible. Starting on day 5 after tumour cell implantation, the
longer (l) and shorter (w) perpendicular axes and the height (h)
of each tumour nodule were measured with callipers every other
day. Metastases of the animals were determined by palpation of
axillar and inguinal lymph nodes. The day when metastases were
ﬁrst palpable the animal was deﬁned as metastasised. To minimise
the pain and distress of the animals no biopsies were taken from
the lymph nodes during the observation time. This was due to
the known fact that the axillar or inguinal lymph nodes were the
most frequent sites of metastasis formation (Fortner et al, 1961;
Weiss et al, 1990). After the end of the experiments when animals
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invasion of the lymph nodes. Tumour volume was calculated
according to the formula Vt=0.8376l6w6h (Weiss et al, 1990).
Animals were observed for 15 to 17 days until tumours reached
a maximum volume of 7 cm. The A-Mel-3 tumour does not have
severe side effects during this early period of growth.
Treatment and experimental groups
The cyclic integrin av antagonist EMD121974 (cyclic Arg-Gly-Asp-
D-Phe(N-methyl)Val) (Dechantsreiter et al, 1999) and the control
peptide EMD135981 (cyclic Arg-b-Ala-Asp-D-Phe(N-methyl)Val)
were synthesised and characterised at Merck KgAa (Darmstadt,
Germany). In pilot studies pharmacokinetics of the peptides were
compared after intravenous and intraperitoneal injection in
hamsters. Plasma half-life time of the cyclic RGD-peptide after
intraperitoneal injection was 47 min, and the area under the curve
was similar after intraperitoneal and intravenous administration. A
subsequent pilot study demonstrated a slightly higher effect on
tumour growth after administration of 30 mg kg
71 every 12 h
compared to 30 mg every 2 days. Therefore, we chose the following
set-up for administration: Peptides were dissolved in PBS
(10 mg ml
71). One day after implantation of tumour cells, animals
were randomly assigned to two groups (n=6) and RGD-peptide
EMD121974 or control-peptide EMD135981 were given i.p. every
12 h (30 mg kg
71 b.w.) until the end of the experiments.
Statistical analysis
Results are presented as mean+s.e.m. Data were evaluated using
Wilcoxon–Mann–Whitney U and Kruskal–Wallis test, respec-
tively (SigmaStat; Jandel Scientiﬁc, San Rafael, CA, USA).
Metastasis analysis was performed according to the Kaplan–Meier
method (Kaplan and Meier, 1958) and the differences were
compared for statistical signiﬁcance using the Cox-F test (Lee,
1975, 1980) with the statistical software program Statistica (Stat-
Soft, Inc, 1997, Tulsa, OK, USA). P values smaller than 5% were
considered to be signiﬁcant.
RESULTS
Functional vascular density
Three days after tumour cell implantation intravital microscopy
already revealed an early vascular network in controls (Figure 1).
Short, thin-walled vessels building anastomosis and loops were
characteristic for tumour vasculature at this day in the control
group (Figure 1A). Intravital microscopy elicited early angiogenesis
on day 3 in the RGD treated group. Sometimes vascular sprouts
were visible without red cell perfusion (Figure 1B). Quantitative
analysis conﬁrmed these observations (Figure 2). Functional vessel
density was signiﬁcantly reduced on day 3 in treated animals in
comparison to controls (32.7+12.1 vs 105.2+11.2 cm
71;
P50.05). Already on day 5, FVD of the control group reached
the maximum value and decreased slightly thereafter until the
end of the experiments (day 13). In the treated group the highest
value of FVD was observed not before day 9, and stayed nearly at
the same level afterwards. On day 13 after tumour implantation,
FVD of controls was signiﬁcantly below values of treated animals
(108.2+10.6 vs 156.9+15.6 cm
71; P50.05).
RBC velocity, vessel diameter and leucocyte–endothelium
interaction
Similar to vessel density, RBC velocity (vRBC) in tumour vessels of
treated animals was markedly below values of controls on day 3
(0.026+0.01 vs 0.12+0.03 mm s
71; P50.05; Figure 3). On days
9 and 13, vRBC was slightly lower in treated animals than in
animals receiving the control peptide. Analysis of vessel diameters
revealed no differences between animals treated with RGD peptide
or control peptide (Figure 4). Leucocyte–endothelium interaction
was almost absent in tumour microvessels of both groups.
Tumour growth in the dorsal skinfold chamber
In early tumour growth on day 5 the size of treated tumours was
similar to controls (Figure 5A,B). After establishment of tumour
microcirculation, rapid growth of the malignant tissue was possible
(Figure 5C). In contrast, growth of the RGD treated tumour was
delayed (Figure 5D). Quantitative data conﬁrmed that treated
tumours were slightly smaller than controls on days 3 and 5,
tumour area was signiﬁcantly reduced on days 9 (20.5+1.4 vs
28.1+3.2 mm
2; P50.05) and 13 (49.1+4.8 vs 80.94+6.1 mm
2;
P50.05; Figure 6). Due to continuous growth, the tumours
obscured the preparations in the control group after 13 days.
Subcutaneous tumour growth and metastasis
Quantitative data demonstrated that A-Mel-3 tumours treated with
the control peptide EMD135981 showed nearly exponential growth
(Figure 7). Administration of the av-antagonist EMD121974
delayed tumour growth for an average of 3.5+0.7 days in compar-
ison to controls: Volume of the treated tumours was signiﬁcantly
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Figure 1 Images of tumour microcirculation 3 days after tumour cell im-
plantation acquired by intravital microscopy after injection of the plasma
marker FITC-Dextran. (A) Tumour vasculature of animals treated with
the control peptide EMD135981 already appears as dense, chaotic struc-
tured network. (B) In the RGD peptide treated group (EMD121974) only
individual sprouts as signs of early angiogenesis were visible. Bar, 50 mm.
Anti-angiogenic tumour therapy with cyclic RGD-peptides
MA Buerkle et al
790
British Journal of Cancer (2002) 86(5), 788–795 ã 2002 Cancer Research UKsmaller in comparison to controls on days 7 until 15. As shown in
the Kaplan–Meier curve (Figure 8) lymph node metastasis were
ﬁrst palpable in two animals of the control group on day 9. Two
days later palpable metastasis was found in all control animals.
In contrast, 50% of the animals treated with RGD peptide were
free of metastasis on day 11. It lasted a total of 17 days, 6 days
longer than in controls, until the last animal of the anti-angiogenic
treated group showed palpable metastasis of this aggressive, very
rapidly growing tumour. At the end of the observations when
tumour size reached a maximum volume of 7 cm, animals were
put to sleep with a high dose of pentobarbital. Metastasis invasion
was histologically conﬁrmed from lymph node biopsies.
DISCUSSION
av-integrins are receptors for a large number of molecules with an
exposed RGD sequence. They are involved in many cell–matrix
recognition and cell–adhesion phenomena (Hynes, 1992; Luscins-
kas and Lawler, 1994). Recent observations revealed that they play
an important role in tumour angiogenesis and metastasis (Brooks
et al, 1994b; Marshall and Hart, 1996). Cyclic RGD peptides have
been developed as selective inhibitors for the av-integrins (Gurrath
et al, 1992; Dechantsreiter et al, 1999). The present study was based
on earlier observations showing a potent inhibitory effect on
tumour angiogenesis using RGD peptides as av-Integrin antagonists
(Eliceiri and Cheresh, 1999). Our results have shown that treat-
ment with the methylated cyclic RGD-peptide resulted in
signiﬁcant reduction of functional vessel density, associated with
retardation of tumour growth and metastasis formation.
Animal model
It is well known that caution must be exercised in the extrapolation
of in vitro observations to the in vivo situation, specially concerning
experiments about tumour angiogenesis (Jain et al, 1997). The
present tumour model (Fortner et al, 1961; Asaishi et al, 1981;
Endrich et al, 1982) was chosen because detailed information
and experience is available about microcirculatory and morpholo-
gic changes of the amelanotic melanoma A-Mel-3 during tumour
angiogenesis and growth. A broad spectrum of knowledge could
be gathered for more than 20 years concerning the tumour proﬁle,
including features like growth rate, invasion of organ systems, and
sensitivity to various therapeutic regimens. The A-Mel-3 is an early
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Figure 2 Functional vessel density (mean+s.e.m.) of control group and
RGD treated group. Measurements were performed 3, 5, 9 and 13 days
after tumour cell implantation by intravital microscopy. Animals were
treated every 12 h (30 mg kg
71) beginning at day 1 after tumour cell im-
plantation until day 13. *P50.05 vs corresponding controls; #P50.05 vs
day 9 and 13;
+P50.05 vs day 3 and 13.
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Figure 3 Red blood cell velocity (mean+s.e.m.) of control group and
RGD treated group. *P50.05 vs corresponding controls; #P50.05 vs
treatment day 9 and day 13.
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Figure 5 Images of the A-Mel-3 tumour in the dorsal skinfold chamber acquired by video macroscopy. (A) Tumour of control group 5 days after tumour
cell implantation. Arrows deﬁne the tumour margin. (C) The same tumour 4 days later. (B) Corresponding tumour of RGD treated group on day 5 and (D)
same tumour on day 9 after tumour cell implantation. Bar 1 mm.
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Figure 6 Area of the A-Mel-3 tumour of the control group and the
RGD treated group in the dorsal skinfold chamber measured on day 3,
5, 9 and 13 after tumour cell implantation (mean+s.e.m.). *P50.05 vs
corresponding controls.
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Figure 7 Tumour growth curves of animals with subcutaneously im-
planted solid A-Mel-3 tumours. Changes in tumour volume are presented
for control animals and following application of cyclic RGD peptide. Values
are indicated as mean+s.e.m. *P50.05 vs controls.
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not show spontaneous remission. It is therefore suitable for testing
the effects of therapeutic modalities. Use of the dorsal skinfold
chamber preparation of a solid tumour combined with intravital
microscopy and subsequent quantitative microvascular analysis
provides an excellent and well established tool for repetitive, direct
evaluation of tumour angiogenesis and microcirculation during a
long period of anti-angiogenic treatment (Borgstroem et al, 1996;
Dellian et al, 1996; Jain et al, 1997; Vajkoczy et al, 2000).
Effects of treatment with RGD-peptides on subcutaneous
tumour growth and metastasis
The growth and metastatic properties of solid tumours are directly
inﬂuenced by the process of angiogenesis (Folkman, 1990). In early
tumour growth, nutrition of tumour cells is guaranteed by diffu-
sion from the environment. Newly formed blood vessels provide
the basis for nutrition and spreading of tumour cells, one of the
most fearsome aspects of cancer (Fidler and Ellis, 1994). In our
experiments subcutaneous tumour growth was nearly exponential
in control animals. Treatment with the RGD peptide integrin
antagonist resulted in signiﬁcant delay of tumour growth until
the end of the experiments. Furthermore, metastasis formation
was inhibited: At the time when lymphatic metastasis was palpable
in all control animals, only 50% of treated animals showed metas-
tasis. It is well known that the risk of metastasis increases with the
number and density of tumour vessels (Weidner et al, 1991, 1993)
and that growth of metastasis may be angiogenesis dependent as
well (Fidler and Ellis, 1994; Saaristo et al, 2000). Furthermore,
growth of metastasis and the primary tumour may be connected:
Folkman and coworkers demonstrated that some primary tumours
inhibit the growth of their metastases by endogenous anti-angio-
genic mediators that are released by the primary tumour
(O’Reilly et al, 1994). Sckell et al (1998) have shown evidence that
anti-angiogenic effects observed at a secondary site correlate with
the tumour burden at the primary site. In our study metastases
became earliest palpable on day 9 after tumour cell implantation
in controls and approximately 50% of the RGD-treated animals
showed metastases with a tumour size comparable to the metastatic
control tumour. Former studies with surgical excision of the A-
Mel-3 have demonstrated that this fast growing, well perfused
tumour metastasises already prior to day 5 after implantation of
tumour cells (Gamarra et al, 1993). Inguinal or axillary metastases
become regularly palpable between days 9 and 11 after tumour cell
implantation in untreated animals or following local tumour ther-
apy (Dellian et al, 1994). Thus, appearance and growth of
metastasis in our tumour model is very closely related to the time
after implantation of tumour cells, but less to the tumour burden
of the animals. Our data from intravital microscopy revealed
already on day 3 an early vascular network in controls making
an early spreading of tumour cells possible, whereas the reduced
vessel density in the RGD-treated group may decrease the probabil-
ity of tumour cell spreading. Exact mechanisms of metastasis
inhibition by anti-av integrin-treatment in this study, however,
are unknown. Reduced metastasis formation may be a consequence
of (a) inhibition of angiogenesis at the primary tumour site and
thus delayed spreading of tumour cells from the primary tumour
and (b) inhibition of angiogenesis in the tumour metastasis, result-
ing in a delay of growth of tumour metastasis.
Based on previous pharmakokinetic studies, anti-angiogenic
therapy was performed by intraperitoneal injections of 30 mg kg
71
of the cyclic RGD-peptide twice a day. Plasma half-life time of the
cyclic RGD-peptide after intraperitoneal injection was 47 min.
However, these data allowed no conclusion on the duration of
the peptides’ binding to av-integrins, which may not last the
12 h until next administration. Remarkably, no side effects were
observed in treated animals indicating low toxicity of the therapeu-
tic regiment: Body weight increased similar in control and treated
animals, and animals showed normal behaviour without signs of
any discomfort.
Effects of treatment with RGD-peptides on functional
vessel density and tumour microcirculation
With our second series of experiments we wanted to address the
question whether the inhibitory effect on the subcutaneous tumour
growth and metastasis may be attributed to changes in tumour
angiogenesis and microcirculation. By intravital microscopy, the
activity of angiogenesis in tumour tissue can be most accurately
quantiﬁed by measurement of functional vessel density (FVD),
i.e. the total length of perfused microvessels per unit area of obser-
vation (Borgstroem et al, 1996; Dellian et al, 1996; Jain et al, 1997;
Vajkoczy et al, 2000).
Comparable to former observations by Endrich et al (1982),
FVD of the control group reached a maximum value at day 5 after
tumour cell implantation, and decreased thereafter whereas
tumours continued to grow. This ‘physiological’ decline of tumour
vessel density in the later growth phases is probably related to
malnutrition and onset of necrosis in the tumour centre: Tumour
blood vessels are more leaky than are vessels of normal tissues
(Gerlowski and Jain, 1986). The increased ﬂuid extravasation leads
to an elevated interstitial ﬂuid pressure (IFP) and low perfusion
pressure in tumour vessels, mainly in the centre of the tumour
(Peters et al, 1980; Wiig et al, 1982). This ﬁnally results in hypoxia
and necrosis formation of central parts of the melanoma, whereas
the tumour margin is still sufﬁciently supplied with blood (Netti et
al, 1999). On that score the data of the RGD treated group showed
three remarkable distinctions: (a) the FVD was signiﬁcantly lower
in early angiogenesis; (b) reached the maximum value not before
day 9; and (c) thereafter stayed nearly at the same level until the
end of the experiments. Vessel growth was especially inhibited
and delayed in the early stage of tumour growth on day 3, whereas
differences in tumour growth became ﬁrst visible later, beginning
on day 9 after tumour implantation in the dorsal skinfold chamber,
presumably as a consequence of inhibition of angiogenesis. The
lack of ‘physiological’ decline of tumour vessel density observed
following anti-av integrin-treatment may be related to continuous
delay of tumour growth.
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
100
80
60
40
20
0
A
b
s
e
n
c
e
 
o
f
 
m
e
t
a
s
t
a
s
i
s
 
(
%
)
1         3         5        7        9       11      13      15      17
Days after tumour cell implantation
Control group (n = 6)
RGD peptide treated group (n = 6)
*P<0.05
control vs
RGD group
Figure 8 Metastasis formation presented as a Kaplan–Meier curve.
Animals of the control group and animals of the RGD peptide treated
group were examined for axillar and inguinal lymph node metastases during
evaluation of tumour growth. Metastasis formation was signiﬁcantly delayed
following therapy with the RGD peptide. *P50.05 vs controls.
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revealed differences only at day 3 following tumour implantation.
At this time point, control tumours already exhibited a dense
vascular network, whereas in tumours following anti-angiogenic
treatment few sprouts as signs of early angiogenesis were visible,
which contained erythrocytes, but often no movement of red blood
cells was seen yet. In contrast to results of studies of the effects of
inhibition of VEGF on tumour microvasculature (Yuan et al, 1995;
Borgstroem et al, 1996), vessel diameters were similar in control
and treated tumours of the present study and increased at best
slightly during tumour growth. These differences are most likely
related to the divergent targets of anti-angiogenic therapeutic regi-
mens. Although leucocyte–adhesion is discussed to be relevant for
angiogenesis (Folkman and Shing, 1992; Ferrara, 1996), leucocyte–
endothelium interaction was almost absent in both groups. Thus
the known reduced expression of leucocyte adhesion molecules in
tumour endothelium (Dellian et al, 1995; Borgstroem et al, 1997)
seems to be not affected by anti-angiogenic therapy directed against
av-integrins.
CONCLUSIONS
Inhibition of av-integrins by a cyclic RGD-peptide resulted in
signiﬁcant reduction of functional vessel density, retardation of
tumour growth and metastasis in vivo. The anti-tumor efﬁcacy
was associated with remarkable low toxicity of this compound.
Administration and dosage of the cyclic RGD-peptide may be
further optimised in future studies. Currently, clinical studies are
performed to test safety of anti-angiogenic therapy with this cyclic
RGD-peptide in humans.
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